Slideshow

February 22, 2018

Adjunctive Cannabidiol Therapy in Schizophrenia

Author(s):

New research looks at the effects of CBD on positive and negative psychotic symptoms, cognitive performance, level of functioning, and the treating psychiatrist’s overall clinical impression.

Related Content

April 30th 2025

April in Review: Updates on the Psychiatric Treatment Pipeline

Leah Kuntz

September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD

April 16th 2025

Treating Schizophrenia: Bringing Together Pharmacists and Clinicians for Patient Care

Michael McGuire, PharmD

May 11th 2021

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

Anita H. Clayton, MD

April 11th 2025

Examining a Case of Acute Late-Pregnancy Psychosis: How Best to Coordinate Care

Cecilia A. Westbrook, MD, PhD Meredith Spada, MD Elizabeth M. Hovis, MD Jacob Larkin, MD Alexandra Nicholas, MD Luke Swider, MD Jonathan Yadlosky, MD Joseph S. DeRenzo, MD Adam P. Dunmore, MD Jennifer L. Kloesz, MD, FAAP Linda Dudas, RNC, MSN, CNL John Silipigni, MSW, MBA Priya Gopalan, MD

April 7th 2025

Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

Grace Koennecke